864 related articles for article (PubMed ID: 2551497)
1. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
[TBL] [Abstract][Full Text] [Related]
3. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity.
Yamashita Y; Ashizawa T; Morimoto M; Hosomi J; Nakano H
Cancer Res; 1992 May; 52(10):2818-22. PubMed ID: 1316228
[TBL] [Abstract][Full Text] [Related]
4. Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance.
Capranico G; Supino R; Binaschi M; Capolongo L; Grandi M; Suarato A; Zunino F
Mol Pharmacol; 1994 May; 45(5):908-15. PubMed ID: 8190107
[TBL] [Abstract][Full Text] [Related]
5. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells.
Capranico G; Soranzo C; Zunino F
Cancer Res; 1986 Nov; 46(11):5499-503. PubMed ID: 3463414
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
Zunino F; Capranico G
Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
[TBL] [Abstract][Full Text] [Related]
7. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
Capranico G; Butelli E; Zunino F
Cancer Res; 1995 Jan; 55(2):312-7. PubMed ID: 7812964
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability.
Kong XB; Rubin L; Chen LI; Ciszewska G; Watanabe KA; Tong WP; Sirotnak FM; Chou TC
Mol Pharmacol; 1992 Feb; 41(2):237-44. PubMed ID: 1311406
[TBL] [Abstract][Full Text] [Related]
9. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.
Wassermann K; Markovits J; Jaxel C; Capranico G; Kohn KW; Pommier Y
Mol Pharmacol; 1990 Jul; 38(1):38-45. PubMed ID: 2164630
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor agents targeting mammalian topoisomerases].
Nakano H
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1550-5. PubMed ID: 1651681
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety.
Ciesielska E; Studzian K; Wasowska M; Oszczapowicz I; Szmigiero L
Cell Biol Toxicol; 2005; 21(3-4):139-47. PubMed ID: 16328893
[TBL] [Abstract][Full Text] [Related]
12. DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs.
Spadari S; Pedrali-Noy G; Focher F; Montecucco A; Bordoni T; Geroni C; Giuliani FC; Ventrella G; Arcamone F; Ciarrocchi G
Anticancer Res; 1986; 6(5):935-40. PubMed ID: 3026237
[TBL] [Abstract][Full Text] [Related]
13. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
[TBL] [Abstract][Full Text] [Related]
14. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
16. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.
Hsiang YH; Liu LF; Wall ME; Wani MC; Nicholas AW; Manikumar G; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Aug; 49(16):4385-9. PubMed ID: 2545341
[TBL] [Abstract][Full Text] [Related]
18. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity and cellular uptake of doxorubicin and its formamidine derivatives in HL60 sensitive and HL60/MX2 resistant cells.
Kik K; Wasowska-Lukawska M; Oszczapowicz I; Szmigiero L
Anticancer Res; 2009 Apr; 29(4):1429-33. PubMed ID: 19414398
[TBL] [Abstract][Full Text] [Related]
20. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity.
Capranico G; Zunino F; Kohn KW; Pommier Y
Biochemistry; 1990 Jan; 29(2):562-9. PubMed ID: 2154250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]